Denali Therapeutics Inc. (DNLI) Dividend History

Company News

• Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

  Denali Therapeutics has initiated a rolling submission of a biologics license application (BLA) for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome (MPS II). The company also has positive ongoing interactions with the FDA on the development of DNL126 for Sanfilippo syndrome type A (MPS IIIA) through the START program.

  GlobeNewswire Inc.
• Biogen (BIIB) Q2 Earnings & Sales Beat, 2024 Guidance Raised

  Biogen reported strong Q2 results, beating earnings and revenue estimates. The company raised its 2024 guidance, driven by growth in new products like Leqembi and Skyclarys, offsetting declines in key multiple sclerosis drugs. However, the termination of a program with Denali Therapeutics weighed on the stock.

  Zacks Investment Research

  Featured Companies: BIIB MRNA SAGE
• Denali Therapeutics director sells over $678k in company stock By Investing.com - Investing.com

  Denali Therapeutics director Steve E. Krognes sold over $678,000 worth of company stock in two separate transactions. The sales were executed under a Rule 10b5-1 trading plan, and Krognes still holds a substantial stake in the company.

  Investing.com
• Goldman Sachs Maintains Buy Rating for Denali Therapeutics: Here's What You Need To Know

  Goldman Sachs has decided to maintain its Buy rating of Denali Therapeutics (NASDAQ:DNLI) and lower its price target from $73.00 to $50.00. Shares of Denali Therapeutics are trading up 2.62% over the last 24 hours, at $20.74 per share. A move to $50.00 would account for a 141.08% increase from the current share price. About Denali Therapeutics Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for ...Full story available on Benzinga.com

  Benzinga
• Why Shares of Denali Therapeutics Are Up Monday

  Analysts maintained their buy ratings on the clinical-stage biotech company.

  The Motley Fool